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Therapeutic Advances in Chronic Disease
Biology and pharmacology of sphingosine-1-
phosphate receptor 1
The past decades have witnessed major advances 
in the treatment of autoimmune and chronic 
inflammatory diseases. A plethora of novel thera-
pies targeting specific molecules involved in the 
inflammatory or immune system activation cas-
cades have become available. These have signifi-
cantly increased our understanding of disease 
pathogenesis and improved the management of 
immune-mediated disorders. However, most of 
the targeted therapies are biological drugs which 
need to be injected, are eliminated slowly (e.g. 
over several weeks) and can lose efficacy or toler-
ability due to their potential immunogenicity. In 
an attempt to overcome these hurdles, pharma-
ceutical research has made considerable efforts to 
develop novel oral targeted therapies for autoim-
mune and chronic inflammatory diseases.
Sphingosine-1-phosphate receptor 1 (S1P1R) is 
one of five known G protein-coupled receptors 
with nanomolar affinity for the lysophospholipid 
sphingosine-1-phosphate (S1P), which is gener-
ated through physiologic metabolism of the cell 
membrane constituent sphingomyelin by all cells 
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[Brinkmann, 2007]. S1P receptors, including 
S1P1R, are widely expressed in many tissues 
[Chun et al. 2010]. S1P1R expression on lympho-
cytes controls their egress from thymus and sec-
ondary lymphoid organs [Cyster and Schwab, 
2012]. Lymphocyte egress requires a gradient of 
S1P concentration, which is established by a high 
S1P concentration in blood and lymph compared 
with a low concentration in the interstitial fluid of 
lymphoid organs [Grigorova et al. 2009].
Synthetic S1P1 receptor modulators disrupt the 
interaction of the physiologic S1P ligand with 
S1P1R by promoting initial activation followed by 
sustained internalization and desensitization of 
S1P1R [Hla and Brinkmann, 2011; Pinschewer 
et  al. 2011]. Experiments conducted in animal 
models of transplant rejection, multiple sclerosis, 
lupus erythematosus, arthritis and inflammatory 
bowel disease with the first-generation, nonselec-
tive S1P receptor modulator, fingolimod, have 
demonstrated the potential efficacy of this mode 
of action across several immune-mediated chronic 
inflammatory conditions [Brinkmann, 2007]. 
Fingolimod is a structural analog of sphingosine 
that is phosphorylated in the body by a sphingo-
sine kinase to generate the bioactive form of the 
drug, fingolimod phosphate, which binds to mul-
tiple S1P receptors [Brinkmann, 2007]. Clinical 
trials in multiple sclerosis (MS) have confirmed 
the efficacy of fingolimod in relapsing MS, but 
not in primary progressive disease, and led to the 
approval of the first oral medication for the treat-
ment of relapsing forms of MS in 2010 [Kappos 
et al. 2010].
The mechanism of action of fingolimod has 
increased our understanding of MS pathogenesis. 
T and B cells, but not natural killer (NK) cells, 
express functional S1P1R and are affected by fin-
golimod [Cyster and Schwab, 2012]. 
Furthermore, S1P1R is differentially expressed 
and regulated in functionally distinct subsets of 
lymphocytes and fingolimod has been shown to 
predominantly affect naïve T cells and central 
memory T cells (TCM) while sparing effector 
memory T cells (TEM), and terminally differenti-
ated effector T cells (TE) in patients with relaps-
ing MS [Mehling et  al. 2008, 2011]. This has 
raised the possibility that, at least in MS, reten-
tion of TCM cells, which include pro-inflamma-
tory T helper 17 (Th17) cells, by fingolimod may 
prevent their accumulation in the cerebrospinal 
fluid (CSF) and subsequent differentiation to TE 
cells in the central nervous system (CNS) [Hla 
and Brinkmann, 2011]. The effects of S1P1R 
modulation on B cells are less well defined. 
Recent data from patients with relapsing MS 
have  shown predominant reduction of memory 
B  cells  and recently activated memory B cells 
(CD38int-high) in peripheral blood after treatment 
with fingolimod [Claes et  al. 2014; Nakamura 
et al. 2014]. As memory B cells are implicated in 
the pathogenesis of MS and other autoimmune 
diseases, these observations suggest another 
potential mechanism underlying the therapeutic 
effects of S1P1R modulators.
Astrocytes, microglia, oligodendrocytes and neu-
rons express various S1P receptors including 
S1P1R, S1P3R and S1P5R. Fingolimod has been 
shown to penetrate the CNS tissues and in vitro 
studies have shown activation of astrocytes and 
oligodendrocytes by fingolimod [Foster et  al. 
2007]. Conditional deletion of S1P1R on neural 
cells in mice reduced the severity of experimental 
autoimmune encephalomyelitis (EAE) and reduc-
tions in the clinical scores were paralleled by 
decreased demyelination, axonal loss and astro-
gliosis [Choi et  al. 2011]. Unfortunately, there 
was no beneficial effect in a recently completed, 
large study of fingolimod in patients with primary 
progressive MS [Lublin et  al. 2015], suggesting 
that the direct effect on CNS cells alone may not 
be sufficient. Taken together, these data suggest 
the possibility of a direct beneficial effect of S1P1R 
modulation in the brain of patients with relapsing 
MS [Dev et al. 2008]; however, its contribution 
to efficacy relative to the immunological effects 
remains unclear.
Initial studies in rodents suggested that modula-
tion of S1P3R on cardiac myocytes by fingolimod 
was associated with a reduction of heart rate (HR) 
by activation of G-protein-coupled inwardly rec-
tifying potassium channels (GIRK) that regulate 
pacemaker frequency, and the shape and dura-
tion of action potentials [Koyrakh et  al. 2005; 
Camm et  al. 2014]. Modulation of S1P2R and 
S1P3R on myofibroblasts by fingolimod was also 
shown to stimulate extracellular matrix synthesis 
[Sobel et al. 2013]. Modulation of these receptors 
on vascular smooth muscle cells appeared to be 
associated with vasoconstriction, leading to the 
slight increase in blood pressure observed with 
fingolimod treatment [Salomone et  al. 2003; 
Watterson et  al. 2005; Hu et  al. 2006; Lorenz 
et al. 2007; Kappos et al. 2010]. These observa-
tions raised the possibility that some side effects 
associated with fingolimod treatment could be 
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avoided by more selective S1P1R modulators, 
thus triggering the search for novel compounds.
Currently, there are several selective S1P1R mod-
ulators in clinical development [Gonzalez-
Cabrera et  al. 2014; Subei and Cohen, 2015]. 
Here we review data and the development status 
of ponesimod, a selective S1P1R modulator devel-
oped by Actelion Pharmaceuticals Ltd.
Ponesimod, a selective, rapidly reversible, 




propylimino-3-o-tolylthiazolidin-4-one) is a 
selective, rapidly reversible, orally active, S1P1R 
modulator. Ponesimod emerged from the discov-
ery of a novel class of S1P1R agonists based on 
the 2-imino-thiazolidin-4-one scaffold (Figure 1) 
[Bolli et  al. 2010]. Ponesimod activates S1P1R 
with high potency [half maximal effective concen-
tration (EC50) of 5.7 nM] and selectivity. Relative 
to the potency of S1P, the potency of ponesimod 
is 4.4 higher for S1P1R and 150-fold lower for 
S1P3R, resulting in an approximately 650-fold 
higher S1P1R selectivity compared with the natu-
ral ligand.
Oral administration of ponesimod has been 
shown to lead to a dose-dependent decrease of 
blood lymphocyte count in animals and humans 
[Piali et al. 2011; Brossard et al. 2013]. In mice 
with delayed-type hypersensitivity, ponesimod 
prevented edema formation, inflammatory cell 
accumulation, and cytokine release in the skin. In 
rats with adjuvant-induced arthritis, ponesimod 
prevented the increase in paw volume and joint 
inflammation [Piali et al. 2011]. Treatment with 
ponesimod of prediabetic non obese diabetic 
(NOD) mice, which spontaneously develop auto-
immune diabetes, prevented disease development 
and ponesimod treatment of diabetic NOD mice 
induced disease remission [You et  al. 2013]. In 
rats, ponesimod was shown to induce a dose-
dependent decrease of blood lymphocyte count, 
which returned to baseline within 48 hours after 
discontinuation of dosing.
Treatment with ponesimod was able to prevent 
the onset and progression of EAE in mice. 
Ponesimod increased survival of the animals even 
when treatment was started after onset of EAE. 
Histological analyses showed that ponesimod 
reduced inflammation, demyelination and axonal 
loss in the brain, cerebellum and spinal cord of 
mice with EAE [Actelion Pharmaceuticals Ltd, 
data on file]. Tissue distribution studies of pone-
simod in rats indicated that ponesimod penetrates 
the brain and spinal cord tissues [Actelion 
Pharmaceuticals Ltd, data on file]. These find-
ings suggest that, in addition to preventing access 
of lymphocytes to the CNS, ponesimod may have 
also direct neuroprotective effects via activation 
of S1P1R on neural cells.
Taken together, these data showed that selective 
modulation of S1P1R using ponesimod is effica-
cious in animal models of lymphocyte-mediated 
tissue inflammation.
Clinical pharmacology of ponesimod
The clinical pharmacology of ponesimod has 
been extensively characterized in several clinical 
studies. To date, over a thousand subjects have 
been exposed to ponesimod including patients 
with MS or psoriasis.
The first in-human study with ponesimod was a 
double-blind, placebo-controlled, ascending, sin-
gle-dose study in healthy male subjects who 
received doses of 1, 3, 8, 20, 50 and 75 mg pone-
simod or placebo [Brossard et  al. 2013]. 
Ponesimod pharmacokinetics (PK) were dose 
proportional with minimal effects of food intake. 
The median time to maximal concentration 
ranged from 2.0 to 4.0 hours, and ponesimod was 
eliminated with a mean half-life varying between 
21.7 and 33.4 hours. Total lymphocyte count in 
peripheral blood was reduced in a dose-dependent 
Figure 1. Chemical structure of ponesimod, 
C23H25N2O4CIS (molecular weight 460.98).
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manner reaching a maximal mean percentage 
(± standard deviation) reduction from baseline of 
70.3 (±2.3%) and returned to normal range 
within 96 hours. Ponesimod reduced T and B cell 
counts, but not the NK cell count, and showed 
differential effects on T-cell subsets with a pre-
dominant reduction of circulating naïve and 
CD4+ T cells versus memory and CD8+ T cells 
while partially sparing CD4+CD25+ regulatory T 
(Treg) cells [D’Ambrosio et al. 2015]. Ponesimod 
was well tolerated. Starting with a dose of 8 mg, 
transient asymptomatic reduction in HR was 
observed.
A multiple-ascending dose study investigated the 
safety, tolerability, PK and pharmacodynamics 
(PD) of 5, 10, 20 and 40 mg once daily (o.d.) 
ponesimod in healthy male and female subjects 
[Brossard et al. 2014]. Ponesimod PK were char-
acterized by a time to maximum concentration 
and an elimination halflife varying from 2.5 to 4.0 
hours and 30.9 to 33.5 hours, respectively, and 
an accumulation of about 2.3-fold. The PK of 
ponesimod in male and female subjects were 
comparable. Ponesimod caused a dose-depend-
ent, sustained decrease in total lymphocyte count 
in peripheral blood. At steady-state ponesimod 
plasma concentrations, the mean maximum 
decrease in total lymphocyte count from baseline 
was 47%, 59%, 74% and 81% in the 5, 10, 20 
and 40 mg dose groups, respectively. Lymphocyte 
count returned to within the normal range within 
1 week of ponesimod discontinuation. Reported 
adverse events (AEs) were mainly related to HR 
reduction, and atrioventricular (AV) conduction 
delays seen after the first dose and effects on pul-
monary function observed mainly at the highest 
dose of 40 mg. Due to the occurrence of sinus 
bradycardia and, in some subjects, AV blocks on 
the first day of dosing, an uptitration regimen 
with a starting dose of 10 mg was introduced to 
reach the 40 mg dose.
An uptitration study of ponesimod to the supra-
therapeutic dose of 100 mg o.d. showed a plateau 
in mean lymphocyte count reduction of approxi-
mately 70% from baseline reached at the 40 mg 
dose level [Hoch et al. 2014]. A dose-dependent 
mean reduction in forced expiratory volume in 1 
second (FEV1) from baseline was observed, with 
a plateau of approximately 30% reduction from 
baseline at 60–100 mg dose levels. Symptoms of 
abdominal pain, dizziness, night sweats, dyspnea 
and chest discomfort were more frequently 
reported with ponesimod than placebo. After 
stopping ponesimod, lymphocyte count and 
FEV1 returned to baseline values within 10 days. 
In addition, inhalation of the short acting β2 ago-
nist, salbutamol, induced a rapid return of FEV1 
close to the baseline values.
The mass balance, PK and metabolism of 
14C-ponesimod were investigated in six healthy 
male subjects [Reyes et  al. 2015]. Fecal excre-
tion was identified as the major route of elimina-
tion of ponesimod while urinary excretion was 
minor. Ponesimod was extensively metabolized 
and 2 pharmacologically inactive metabolites, 
M12 and M13, were detected in the circulation 
corresponding to 8.1% and 25.7%, respectively, 
of the total drug-related exposure (AUC0–∞) in 
plasma.
A clinical study in Japanese and Caucasian sub-
jects showed no relevant differences in the PK 
and PD of ponesimod across ethnic groups and 
sexes [Reyes et al. 2014b].
Similarly to fingolimod, ponesimod is teratogenic 
in animals and the use of effective contraception 
is necessary for women of child-bearing potential. 
A drug–drug interaction study in healthy women 
showed no clinically relevant PK interactions 
between ponesimod and combined oral contra-
ceptives [Reyes et al. 2014a].
A thorough QT study indicated a mild prolonga-
tion of QTc interval by ponesimod with the larg-
est mean increase of 6.9 s and 9.1 ms for doses of 
40 and 100 mg, respectively [Hoch et al. 2015a]. 
Based on concentration-effect analysis, QTc pro-
longation caused by 20 mg, currently the highest 
therapeutic dose, was predicted to be a mean 
increase of 4.4 ms [90% confidence interval (CI): 
2.9–5.9 ms], which is below the level of clinical 
concern.
Based on the data obtained in healthy subjects, a 
PK/PD model of the effect of ponesimod on 
peripheral blood lymphocyte count has been 
developed to identify doses to be tested in subse-
quent studies in patients [Krause et al. 2014].
The PK and PD of ponesimod were also investi-
gated in the psoriasis and MS phase II studies 
(Table 1). PK and PD characteristics of ponesi-
mod in patients with psoriasis or MS were found to 
be similar to those observed in healthy subjects.
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Efficacy and safety of ponesimod in MS
Efficacy in MS
A double-blind, placebo-controlled, dose-finding 
phase IIb study evaluated the efficacy, safety and 
tolerability of ponesimod in the treatment of 
relapsing remitting MS [ClinicalTrials.gov identi-
fier: NCT01006265] (Table 1) [Olsson et  al. 
2014]. A total of 464 patients were randomized 
across 94 centers in 23 countries (in Europe, 
Australia, Canada and USA) between October 
2009 and November 2010 to receive ponesimod 
10, 20 and 40 mg o.d. or placebo for 24 weeks. 
Baseline demographic and disease characteristics 
of patients were well balanced across groups.
The primary efficacy endpoint of cumulative 
number of new gadolinium-enhancing (Gd+) 
lesions per patient detected on T1-weighted 
magnetic resonance imaging (MRI) scans from 
weeks 12 to 24 was significantly and dose-
dependently reduced by 43%, 83% and 77% 
with ponesimod 10, 20 and 40 mg, respectively, 
compared with placebo (Table 2). Although the 
study was not designed to show an effect on 
relapses, the rate of relapses was reduced by 
ponesimod treatment. The annualized relapse 
rate (ARR) up to week 24 was approximately 
0.33, 0.42 and 0.25 in the 10, 20 and 40 mg 
ponesimod groups, respectively, compared with 
0.525 in the placebo group. Peripheral blood 
Table 1. Ponesimod phase II and III clinical studies (completed and ongoing).
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lymphocyte count was rapidly reduced with 
ponesimod treatment in a dose-dependent man-
ner. Mean reductions from baseline to week 24 
were 50%, 65% and 69% for ponesimod 10, 20 
and 40 mg, respectively, compared with 3% in 
the placebo group. Patients completing the 24 
weeks of treatment in the phase II core study 
were eligible to enter a dose-blinded extension 
with ponesimod 10, 20 and 40 mg.
A total of 353 patients, out of the 393 who com-
pleted the core study, entered the long-term 
extension trial [ClinicalTrials.gov identifier: 
NCT01093326] (Table 1). Patients who 
received active treatment during the initial 24 
weeks continued treatment with the same dose 
of ponesimod, whereas patients who received 
placebo were randomized in a 1:1:1 ratio to 
receive either 10, 20 or 40 mg ponesimod. 
Following completion and analysis of results 
from the placebo-controlled phase IIb core 
study, patients receiving 40 mg ponesimod in the 
extension study were switched to 10 or 20 mg 
ponesimod in a 1:1 ratio, while patients who 
received 10 or 20 mg ponesimod continued with 
the same dose. An interim analysis of the exten-
sion study was performed to help in planning for 
the phase 3 studies [Pozzilli et al. 2013]. At the 
cutoff date of this interim analysis, treatment 
was ongoing in 309 patients and the mean treat-
ment duration in all treatment groups ranged 
between 99.5 and 119.7 weeks for the combined 
core plus extension phase II study.
The ARR in patients continuously treated with 
ponesimod 10, 20 or 40 mg in the core and 
extension studies was 0.24, 0.21 and 0.14, 
respectively, suggesting a dose-dependent 
reduction of relapse frequency with ponesimod. 
Additional analysis of ARR by treatment peri-
ods showed decreasing relapse rates with time 
and a clearer dose-dependent effect on relapses 
in the second year of treatment. Consistent 
with a dose-dependent reduction of disease 
Table 2. Main efficacy results of ponesimod phase II studies.
Endpoints Placebo Ponesimod 10 mg Ponesimod 20 mg Ponesimod 40 mg
Phase IIb study in relapsing remitting multiple sclerosis
Mean (SD) cumulative 
number of new T1 Gd+ 










Treatment effect ratio 







Annualized relapse rate 









Treatment effect ratio 
versus placebo (95% CI)
– 0.632 (0.332–1.202) 0.793 (0.440–1.432) 0.478 (0.240–0.954)
p value – 0.1619 0.4420 0.0363
Phase IIb study in moderate-to-severe chronic plaque psoriasis
% PASI75 at week 16* n = 67
13.4




p value <0.0001 <0.0001








p value <0.0001 <0.0001
DLQI score mean 
change (SD) at week 16*
n = 67
−2·5 (±5·94)




p value 0.0003 0.0004
*All treated analysis set.
$Per protocol analysis set.
CI, confidence interval; DLQI, Dermatology Life Quality Index; Gd, gadolinium; MRI, magnetic resonance imaging; PASI, 
Psoriasis Area and Severity Index; PGA, physician global assessment; SD, standard deviation.
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activity by ponesimod, the number of total T1 
Gd+ lesions and the number of new or enlarg-
ing T2 lesions detected by MRI after 72 weeks 
of treatment were consistently lower in patients 
receiving 20 and 40 mg compared with those 
receiving 10 mg ponesimod. Overall, the avail-
able phase II data indicated a sustained dose-
dependent reduction in the number of brain 
inflammatory lesions and reduced rates of 
relapses with ponesimod. The lymphocyte 
reducing effect and the efficacy of ponesimod 
reached a plateau with 20 mg o.d.
Safety in MS
In the phase II core study, ponesimod was 
generally safe and well tolerated. The majority of 
AEs were of mild or moderate intensity and the 
proportion of patients who had at least 1 treat-
ment-emergent AE was similar across the ponesi-
mod groups (73.9–77.2%) compared with the 
placebo group (74.4%). During the 24 weeks’ 
treatment period, 6.5%, 6.1% and 2.5% of the 
patients in the ponesimod 10, 20 and 40 mg, 
respectively, reported at least 1 serious adverse 
event (SAE) compared with 4.1% in the placebo 
group. The proportion of patients who prema-
turely discontinued study treatment due to AEs 
in the ponesimod 10, 20 and 40 mg groups was 
11.1%, 5.3% and 13.4%, respectively, compared 
with 2.5% in the placebo group. Treatment-
emergent AEs reported with higher incidence in 
ponesimod groups were anxiety, cough, dyspnea, 
influenza, insomnia, peripheral edema, dizziness 
and increased alanine transaminase (ALT). The 
incidence of dyspnea and peripheral edema 
appeared to be dose-related and had an early 
onset.
The interim analysis from the phase II exten-
sion study did not identify new or unexpected 
safety signals associated with longer exposure 
to ponesimod.
In the phase II core study, all patients in the 
ponesimod groups received 10 mg on the first day 
and were uptitrated to 20 or 40 mg after 1 and 2 
weeks, respectively. After the first dose of 10 mg 
ponesimod, there was a transient reduction in HR 
that reached a maximum of approximately 
16 beats per minute (bpm), compared with 4 bpm 
on placebo, from baseline at 2–3 hours post dose 
and returned to pre dose values 6 hours post dose. 
The effect of subsequent uptitration to 20 and 
40 mg on HR was negligible. AEs of bradycardia 
and second degree AV block Mobitz Type I were 
reported in 2% and 0.9%, respectively, of patients 
receiving ponesimod 10 mg on day 1.
The rate of infections was not increased in the 
ponesimod groups compared with the placebo 
group in the phase II core study. Lymphocyte 
count reduction was dose-dependent, sustained 
with ponesimod treatment, and fully reversible 
within 1 week of treatment discontinuation.
There was a dose-dependent decrease in FEV1 
with ponesimod treatment. In the phase II core 
study, the mean percentage change in FEV1 
from baseline to week 24 was −0.6%, −5.2%, 
−6.0% and −10.3% in the placebo and ponesi-
mod 10, 20 and 40 mg groups, respectively. In 
the subgroup of patients who discontinued treat-
ment prematurely or did not enter the extension 
study, FEV1 returned to baseline values within 1 
week of treatment discontinuation. There was 
also a decrease in forced vital capacity (FVC) 
with ponesimod treatment, but this was smaller 
than the decrease seen for FEV1 and also revers-
ible, suggesting a functional obstructive change 
induced by ponesimod. In the phase II core 
study, the proportion of patients with respiratory 
AEs, consisting mainly of mild or moderate 
dyspnea, was higher in the ponesimod than in 
the placebo group (placebo, 6.6%; ponesimod 
10 mg, 9.3%; ponesimod 20 mg, 16.7%; ponesi-
mod 40 mg, 31.9%).
There were increases in liver transaminases with 
ponesimod treatment. In the phase II core study, 
the proportion of patients with a >3-fold increase 
in ALT above the upper limit of the normal 
range was 2.8%, 4.5% and 4.2% in the ponesi-
mod 10, 20 and 40 mg arms, respectively, com-
pared with none in the placebo group. These 
increases were asymptomatic, not associated 
with bilirubin elevations, and were reversible 
after treatment discontinuation or even upon 
continued treatment.
There were four cases of macular edema (one on 
placebo and three on ponesimod) reported in the 
phase II core study, but only one (on ponesimod) 
was confirmed while a second confirmed case 
occurred in the extension study. Both confirmed 
cases occurred within the first 3 months of initiat-
ing ponesimod treatment and resolved without 
sequelae after discontinuation.
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Current assessment of ponesimod benefit-risk 
in MS
Based on the efficacy and safety data available 
from the phase II core and extension studies, 
ponesimod appears to have a favorable benefit–
risk profile for the treatment of patients with 
relapsing MS. Oral treatment with ponesimod 
significantly and dose-dependently reduced the 
number of inflammatory lesions in the brain 
and was associated with a numerical reduction 
of relapse rates. Although comparison across 
different studies has several limitations and 
should be interpreted with caution, the magni-
tude of treatment effects with ponesimod in 
MS appears overall comparable with that asso-
ciated with fingolimod treatment [Kappos et al. 
2006, 2010]. However, in contrast to fingoli-
mod, a clear dose–response relationship was 
identified for ponesimod, reaching a plateau of 
PD effect and therapeutic efficacy with 20 mg 
o.d. dosing.
Ponesimod was generally well tolerated at doses 
of 10 and 20 mg, while the 40 mg dose was associ-
ated with an increased incidence of AEs leading 
to treatment discontinuation, particularly in rela-
tion to respiratory function effects and symptoms 
of dyspnea. The 20 mg dose appears to provide an 
optimal benefit–risk balance for treatment of MS 
patients with ponesimod, but more data are 
needed from the ongoing phase II extension study 
and from other studies to provide compelling evi-
dence. First-dose cardiac effects observed with 
ponesimod appeared of similar nature to those 
described with fingolimod [Kappos et al. 2010], 
but in more recent studies with ponesimod an 
optimized uptitration regimen is used to mini-
mize these effects [Hoch et al. 2015b]. The S1P1R 
selectivity of ponesimod may provide safety 
advantages over fingolimod, but these may need 
long-term observation to become apparent.
A distinctive feature of ponesimod in comparison 
with fingolimod is its shorter halflife and corre-
sponding rapid reversibility of effects on the 
immune system. Lymphocyte count in peripheral 
blood returned to the normal range within 1 week 
after stopping ponesimod compared with 1–2 
months after stopping fingolimod. The quicker 
elimination of ponesimod may be an advantage in 
managing serious or opportunistic infections, it 
may be beneficial in case of vaccination or preg-
nancy, and it may also help to prevent sequelae or 
complications in case of AEs such as macular 
edema, pulmonary function changes and liver 
enzyme elevations. A phase III study is currently 
ongoing to establish the benefit–risk of ponesi-
mod in patients with relapsing MS [ClinicalTrials.
gov identifier: NCT02425644] (Table 1).
Efficacy and safety of ponesimod in 
psoriasis
Efficacy in psoriasis
The rationale to apply ponesimod in psoriasis is 
based on the concept that psoriasis is a T-cell 
mediated inflammatory skin disease. Blocking 
lymphocyte recirculation from secondary lym-
phoid organs therefore appeared a promising and 
novel therapeutic approach to improve psoriasis 
by reducing the recruitment of pathogenic T cells 
into the skin.
The first study of ponesimod in psoriasis was a 
small proof-of-concept, randomized, double-
blind, placebo-controlled study in 66 patients 
with moderate- to-severe chronic plaque psoriasis 
treated with o.d. 20 mg ponesimod or placebo 
[ClinicalTrials.gov identifier: NCT00852670] 
(Table 1). The study showed ponesimod was 
generally well tolerated and might provide a ben-
efit to these patients.
A double-blind, randomized, placebo-controlled, 
dose-finding phase IIb study evaluated the effi-
cacy, safety and tolerability of ponesimod for 
the  treatment of moderate-to-severe chronic 
plaque psoriasis [ClinicalTrials.gov identifier: 
NCT01208090] (Table 1) [Vaclavkova et  al. 
2014]. A total of 326 patients were randomized 
across 58 centers in 15 countries between 
September 2010 and October 2012 to receive 
o.d. ponesimod 20 or 40 mg, or placebo for 16 
weeks. Patients with at least a partial improve-
ment at 16 weeks continued ponesimod or were 
switched to placebo until week 28. Baseline 
demographic and disease characteristics of 
patients were well balanced across groups and 
consistent with a population of patients in need of 
systemic psoriasis treatment.
The primary efficacy endpoint of a reduction in 
Psoriasis Area and Severity Index (PASI) score of 
at least 75% from baseline (PASI75) at week 16 
was met in 46.0% and 48.1% of patients in the 20 
and 40 mg ponesimod groups, respectively, com-
pared with 13.5% in the placebo group (Table 2). 
At week 16, physician global assessment (PGA) 
scores of 0 or 1 were observed in 27.8% and 
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32.3% of patients in the 20 and 40 mg ponesimod 
groups, respectively, compared with 4.5% in the 
placebo group. A PASI90 score at week 16 was 
met in 3.0%, 14.3% and 24.8% of patients in the 
placebo, ponesimod 20 and 40 mg groups, respec-
tively. Improvements in quality of life were also 
reported more frequently by patients receiving 
ponesimod than placebo.
The PASI score started to improve 3 weeks after 
initiation of ponesimod treatment and continued 
to do so during the induction period. PASI 
scores improved further after 16 weeks in those 
patients who continued ponesimod treatment 
until the end of the study, while patients began 
to lose efficacy approximately 4 weeks after 
switching to placebo. Peripheral blood lympho-
cyte count was rapidly reduced with ponesimod 
treatment to a similar extent as seen in patients 
with MS. Mean reductions of lymphocyte count 
from baseline to week 16 were around 2%, 56% 
and 65%, for the placebo, ponesimod 20 and 
40 mg groups, respectively. Lymphocyte count 
remained stable in patients who continued pone-
simod treatment up to week 28. In patients who 
switched to placebo, lymphocyte count recov-
ered quickly to roughly baseline levels after stop-
ping ponesimod.
The loss of clinical benefits in patients who 
switched from ponesimod to placebo was grad-
ual, starting approximately 4 weeks after stopping 
ponesimod treatment and it was delayed com-
pared with the restoration of lymphocyte count in 
peripheral blood. This delay suggests that patho-
genic lymphocytes need to return to the circula-
tion, enter the skin, and become activated to 
trigger the formation of new plaques. These 
observations also support the notion that a con-
tinuous recruitment of T cells from lymphoid 
organs rather than a persistent activation of a pri-
ori skin-resident T cells is required to induce and 
maintain disease activity in psoriasis [Diluvio 
et al. 2006; Gaide et al. 2015].
Assessment of the patients’ perception of joint 
pain in a subgroup of patients (n = 44) who had 
psoriatic arthritis suggested that ponesimod treat-
ment may also have a beneficial effect on joint 
involvement in psoriatic arthritis.
Safety in psoriasis
Ponesimod appeared generally well tolerated in 
patients with psoriasis.
In the dose-finding phase IIb study, most AEs 
were of mild or moderate intensity. SAEs were 
reported in 1.5%, 4.0% and 3.8% patients in the 
placebo, ponesimod 20 and 40 mg groups, respec-
tively. The proportion of patients who prema-
turely discontinued study treatment due to AEs 
in the ponesimod 20 and 40 mg groups was 7.9% 
and 10.5%, respectively, compared with 1.5% in 
the placebo group. Treatment-emergent AEs 
reported with higher incidence in ponesimod 
groups included dyspnea, dizziness, increased 
ALT or aspartate transaminase (AST), and 
bradycardia.
All patients in the ponesimod groups received 
10 mg on the first day and were later uptitrated to 
20 or 40 mg. After the first dose of 10 mg ponesi-
mod, there was a transient reduction in HR that 
reached a maximum of approximately 13 bpm 
(compared with 2 bpm on placebo) from baseline 
at 2–3 hours post dose and returned close to pre 
dose values 6 hours post dose. As seen in the MS 
phase II study, the effect on HR of subsequent 
uptitration to 20 and 40 mg was negligible. AEs of 
bradycardia and second-degree AV block were 
reported more frequently in the ponesimod 
groups, almost exclusively on day 1.
The rate of infections was similar across all treat-
ment groups. Lymphocyte count reduction was 
dose-dependent, sustained with ponesimod treat-
ment, and fully reversible after 1 or 2 weeks after 
treatment discontinuation.
There was an early, dose-dependent decrease in 
FEV1 with ponesimod treatment. The mean 
change in FEV1 from baseline to week 8 was 
0.1%, −5.1% and −10.1% in the placebo and 
ponesimod 20 and 40 mg groups, respectively. As 
seen in MS, the reduction of FVC with ponesi-
mod was less pronounced compared with FEV1. 
For patients who switched at week 16 from pone-
simod to placebo, the FEV1 returned to baseline 
values within 2 weeks of ponesimod discontinua-
tion. The proportion of patients who reported an 
AE of dyspnea was higher in the ponesimod 
groups compared with placebo (placebo, 1.5%; 
ponesimod 20 mg, 11.1%; ponesimod 40 mg, 
26.3%).
There were increases in aminotransferases with 
ponesimod treatment. The proportion of patients 
with >3-fold increase in aminotransferases above 
the upper limit of the normal range was 11.3% 
and 8.4% in the ponesimod 20 and 40 mg groups, 
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respectively, compared with 3.1% in the placebo 
group. These increases were asymptomatic, not 
associated with bilirubin elevations, and were 
reversible after treatment discontinuation or even 
on continued treatment.
There was one confirmed case of macular edema 
which occurred within the first 3 months of initiat-
ing ponesimod treatment and resolved shortly 
after treatment discontinuation without sequelae.
Current assessment of ponesimod benefit-risk 
in psoriasis
Phase II study results indicated that ponesimod 
may be efficacious for treatment of moderate-to-
severe chronic plaque psoriasis. Although the effi-
cacy seen with ponesimod cannot be directly 
compared with that achieved in other studies, it 
appears similar to that of the tumor necrosis 
factor-α (TNF-α) antagonist, etanercept, and 
better than that of methotrexate and the phos-
phodiesterase 4 inhibitor apremilast, an oral small 
molecule recently approved for treatment of pso-
riasis and psoriatic arthritis [Kavanaugh et  al. 
2014; Papp et al. 2015]. Both ponesimod doses 
showed a similar level of efficacy. Thus it remains 
to be determined whether doses lower than 20 mg 
could also be effective.
In the population enrolled in the phase II study, 
which excluded psoriasis patients with some com-
mon cardiovascular or metabolic comorbidities, 
ponesimod was generally well tolerated, particu-
larly at the dose of 20 mg.
First-dose cardiac effects with ponesimod were of 
a similar magnitude to those seen in the MS phase 
II trial. As for MS patients, an optimized titration 
regimen might be used to minimize these effects 
and improve the benefit–risk balance in this 
population.
The magnitude of lymphocyte count reduction, 
pulmonary function effects and incidence of 
infections observed with ponesimod in psoriasis 
patients were also similar to those seen in patients 
with MS. Aminotransferase elevations were 
apparently more frequent in patients with psoria-
sis, but were also not associated with any sign or 
symptoms of potential hepatotoxicity.
The finding that ponesimod may provide a bene-
fit to skin as well as joint disease in patients with 
psoriatic arthritis suggests potentially broad 
applications of ponesimod for the treatment of 
various immune-mediated diseases in which T 
cells play a predominant pathogenic role. Further 
studies will be needed to better characterize the 
benefit–risk profile of ponesimod in psoriasis.
A gradual dose titration regimen to 
minimize first-dose effects of ponesimod
In humans, activation of S1P1 receptors on car-
diomyocytes during initiation of treatment with 
an S1P1R modulator leads to transient HR 
decreases and infrequently AV conduction delays 
[Peters and Alewijnse, 2007; Camm et al. 2014]. 
These effects initially observed with the nonselec-
tive S1PR modulator fingolimod were later found 
to occur also with selective S1P1R modulators in 
humans. Acute occurrence of bradycardia and, in 
some cases, AV blocks seen after the initial fin-
golimod intake, requires electrocardiography 
(ECG) monitoring for at least 6 hours after 
administration of the first dose [Novartis, 2015]. 
HR decrease with fingolimod is maximal approxi-
mately 6 hours after the first dose and diminishes 
with the second and subsequent doses. With con-
tinued dosing of fingolimod, S1P1R becomes 
internalized and unable to signal on cardiomyo-
cytes and thus the HR gradually returns to base-
line within 1 month of chronic treatment 
[Novartis, 2015].
Clinical data from over a thousand subjects 
treated with ponesimod have consistently shown 
a dose-dependent HR reduction following first-
dose administration. This effect is transient and 
due to initial activation of S1P1R by ponesimod 
before internalization and desensitization of the 
receptor. The desensitization phenomenon 
observed for the effect on HR and AV conduc-
tion suggested that the effect could be mitigated 
by initiating treatment with a low dose followed 
by uptitration to the target dose. A study in 
guinea pigs, a preclinical model in which S1P1R 
regulates AV conduction, had shown that a pro-
gressive dose titration regimen could signifi-
cantly reduce the effects of ponesimod on AV 
conduction [Rey et  al. 2013]. On the basis of 
these observations, different uptitration regi-
mens were investigated to minimize the first-
dose effects of ponesimod on HR and AV 
conduction in humans.
An uptitration regimen of ponesimod o.d. start-
ing with 10 mg for 7 days, followed by 20 mg for 7 
days, then followed by 40 mg was initially 
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investigated in phase I studies [Brossard et  al. 
2014] and later implemented in the phase II stud-
ies of psoriasis and MS. This uptitration regimen 
was able to reduce acute changes in HR and AV 
conduction but bradycardia and second degree 
AV blocks, mostly asymptomatic, were still 
observed in a small proportion of subjects after 
first-dose administration and required monitor-
ing for a period of 6 hours.
Based on the sustained S1P1R desensitization 
induced by ponesimod, PK/PD modeling was 
used to design new uptitration regimens with the 
objective to minimize the acute effects of ponesi-
mod on HR and AV conduction. An early study 
comparing three different uptitration regimens of 
ponesimod in healthy subjects suggested that a 
dose around 2.5 mg might be sufficient to start 
inducing S1P1R desensitization while causing a 
very small first-dose effect [Scherz et  al. 2015]. 
The study also investigated the duration of S1P1R 
desensitization upon 1–3 days interruption of a 
maintenance dosing regimen of 20 mg o.d. The 
first-dose cardiac effects seen upon re-initiation 
with 20 mg were small even after 3 days interrup-
tion, thus indicating that S1P1R desensitization 
was sustained for at least 3 days after stopping 
treatment.
A more recent study in 32 healthy male and 
female subjects compared a novel gradual upti-
tration regimen of ponesimod to the uptitration 
regimen used in phase II studies [Hoch et  al. 
2015b]. The novel uptitration regimen of ponesi-
mod consisted of a starting dose of 2 mg given for 
2 days, followed by administration of 3 and 4 mg 
for 2 days at each dose, followed by 5, 6, 7, 8 and 
9 mg for 1 day at each dose, 10 mg for 2 days and 
then a 20 mg maintenance dose. This gradual 
uptitration regimen was able to minimize the 
effects of ponesimod on HR and AV conduction. 
Mean decrease of HR from baseline following 
the first dose was smaller with the gradual upti-
tration compared with the previous uptitration (a 
decrease of 6 versus 12 bpm). The effects on HR 
and AV conduction were smaller during the 
entire 2-week regimen with the novel uptitration 
compared with the previous one. There were no 
SAEs or AEs leading to treatment discontinua-
tion and no AEs of bradycardia or AV blocks 
reported with the gradual regimen. Dizziness and 
headache AEs were less frequently reported with 
the new regimen and fewer subjects had occur-
rences of a marked HR decrease with the novel 
uptitration.
Overall, the novel, gradual uptitration was better 
than the previous one to minimize the effects of 
ponesimod on HR and AV conduction. This 
gradual uptitration regimen is currently imple-
mented in ponesimod clinical studies. Data from 
the ongoing studies will help to determine whether 
first-dose monitoring of patients on site may be 
reduced or even avoided with the novel uptitra-
tion regimen.
Future of ponesimod for the treatment of MS 
and other lymphocyte-driven diseases
Development in MS
The extensive clinical experience gained with 
ponesimod allowed the selection of an optimized 
uptitration dosing regimen to minimize first-dose 
cardiac effects and of a maintenance dose of 
20 mg o.d. to achieve the desired level of thera-
peutic efficacy for phase III studies.
A multinational, randomized, double-blind, 
active-control phase III study of ponesimod in 
relapsing MS, OPTIMUM [ClinicalTrials.gov 
identifier: NCT02425644) (Table 1), has recently 
been started. The OPTIMUM study is evaluating 
the efficacy and safety of ponesimod in patients 
with relapsing MS. This study will randomize 
approximately 1100 patients in a 1:1 ratio to 
receive 20 mg ponesimod or 14 mg teriflunomide 
orally o.d. for 2 years. The primary objective of 
the trial is to assess whether ponesimod is supe-
rior to teriflunomide in reducing the ARR over 
108 weeks. Secondary endpoints include time to 
12-week confirmed disability accumulation, time 
to first confirmed relapse, cumulative number of 
combined unique active lesions of the brain, and 
percent change in brain volume from baseline to 
week 108.
The study is enrolling adult male and female sub-
jects aged 18–55 years with an established diag-
nosis of relapsing MS, as defined by the 2010 
revision of the McDonald Diagnostic criteria, 
with relapsing course from onset (i.e. relapsing 
remitting MS or secondary progressive MS with 
superimposed relapses). Patients are required to 
have active disease based on at least 1 MS attack 
within 12 months or 2 MS attacks within 24 
months or at least 1 Gd+ lesion in the brain or 
spinal cord on an MRI performed within 6 
months of study entry. The trial permits inclusion 
of patients with secondary progressive MS with 
superimposed relapses up to a maximum of 15%. 
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This will allow the evaluation of the benefit–risk 
profile of ponesimod in this group of patients, 
who have often not been included in pivotal trials 
of medications approved for treatment of relaps-
ing MS.
This study will be the first to compare the efficacy 
and safety of two oral treatments in relapsing MS 
patients. Teriflunomide is a first-line oral medica-
tion, approved for the treatment of patients with 
relapsing MS in 2013 [O’Connor et  al. 2011, 
2013; Freedman, 2013]. Both ponesimod and 
teriflunomide are given orally o.d., which facili-
tates blinding and improves patient compliance in 
the clinical trial.
The OPTIMUM study has a number of unique 
features. Nonconventional MRI techniques of 
magnetization transfer ratio (MTR) and double 
inversion recovery are implemented at selected 
centers to investigate the effect of ponesimod on 
grey matter lesions and to measure the changes in 
myelin density in normal appearing white matter 
and focal lesions, respectively. A patient-reported 
outcome measure of fatigue in relapsing MS, 
developed according to FDA guidance [Hudgens, 
2015], is being used for the first time to measure 
the effect of ponesimod on fatigue-related symp-
toms. A purpose-designed e-diary is used to 
enhance and monitor treatment compliance of 
patients in the trial.
A substudy of OPTIMUM will aim to collect 
patients’ preferences and value judgments for 
selected treatment outcomes via a purpose-
designed questionnaire. The substudy has a tar-
get of approximately 360 patients and the data 
collected will be analyzed using the Measuring 
Attractiveness by a Categorical Based Evaluation 
Technique (MACBETH) [Bana e Costa and 
Vansnick, 1999]. This approach, implemented 
for the first time in an interventional MS trial, 
may help to shape future healthcare decisionmak-
ing based on patient preferences [Wilson et  al. 
2014].
Patients who will complete the 108 weeks of 
treatment in the OPTIMUM study will have the 
possibility to enter an open-label, long-term 
extension study in which all patients will receive 
20 mg o.d. ponesimod. The main objectives of 
this extension study will be to evaluate the long-
term safety and tolerability, and the effect on dis-
ease control of ponesimod as well as the effects of 
re-initiating ponesimod treatment after interrup-
tion and of switching from teriflunomide to pone-
simod treatment.
Finally, the long-term efficacy, safety and tolera-
bility of 10 and 20 mg ponesimod will continue to 
be evaluated in the long-term dose-blinded, phase 
II extension study.
These and potentially other studies are expected 
to support the benefit–risk assessment of ponesi-
mod for the treatment of patients with relapsing 
forms of MS.
Development in chronic graft versus host 
disease
Chronic graft versus host disease (GVHD) is a 
pleomorphic syndrome with autoimmune-like 
features, which represents the most serious and 
common long-term complication of allogeneic 
hematopoetic stem cell transplantation (HSCT). 
The prognosis of patients with chronic GVHD is 
poor, especially for glucocorticoid refractory dis-
ease [Lee and Flowers, 2008; Martin et al. 2011]. 
The pathophysiology of chronic GVHD is com-
plex and involves both autoreactive and alloreac-
tive T and B lymphocytes [Wolff et  al. 2011]. 
Fingolimod has shown beneficial effects in an ani-
mal model of chronic GVHD [Huu et al. 2013], 
suggesting a potential role of S1P1R modulators 
in the treatment of this condition.
Based on these premises, a phase II study has 
recently been initiated with ponesimod in patients 
with chronic GVHD. This is a prospective, multi-
center, open-label, intra-subject dose-escalation 
study [ClinicalTrials.gov identifier: NCT02461134] 
(Table 1). The study is designed to investigate the 
biological activity, safety, tolerability and PK of 
ponesimod in subjects with symptomatic moderate 
or severe chronic GVHD inadequately responding 
to first- or second-line therapy.
Approximately 30 subjects will be enrolled to 
receive ponesimod in escalating doses of 5, 10 
and 20 mg over the core treatment period of 24 
weeks. The study will be conducted at approxi-
mately 10 sites in the USA. Subjects successfully 
completing the initial 24 weeks of the study have 
the possibility to restart ponesimod for an exten-
sion treatment course of 96 weeks should their 
chronic GVHD progress within a defined time-
frame after stopping ponesimod.
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Patients with chronic GVHD may be particularly 
fragile due to the underlying causes of and proce-
dures associated with HSCT, which include 
treatment with multiple cytotoxic and immuno-
suppressive medications. An important goal of 
this study is to investigate the safety and tolerabil-
ity of ponesimod in this patient population. 
Equally important is to explore the effects of 
ponesimod on the newly reconstituted immune 
system of these patients and to investigate its 
potential beneficial effects on the disease.
Conclusion
Ponesimod is an orally active, selective S1P1R 
modulator developed by Actelion Pharmaceuticals 
Ltd. Ponesimod has successfully completed phase 
II studies in relapsing remitting MS and moderate-
to-severe chronic plaque psoriasis showing thera-
peutic efficacy in these conditions and a potential 
to treat other immune-mediated disorders. The 
selectivity for S1P1R and the rapid onset and 
reversibility of pharmacological effects of ponesi-
mod constitute important differences from the 
first-generation S1PR modulator fingolimod, and 
have the potential for an improved tolerability and 
safety profile. An optimized uptitration regimen 
for ponesimod treatment initiation can minimize 
the first-dose effects associated with modulation of 
the S1P1R on cardiomyocytes and might require a 
less burdensome monitoring than fingolimod. A 
phase III study is ongoing to establish ponesimod’s 
place among the available treatment options for 
patients with relapsing MS. A phase II study is also 
ongoing to investigate the potential utility of pone-
simod for the treatment of patients with GVHD.
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